EN DE
Watch Kronox Lab Sciences Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Kronox Lab Sciences Ltd (KRONOX) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of Kronox Lab Sciences Ltd stock ₹137, price ₹181, that is 24.7% below the price, quality 70 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Basic Materials IN · ISIN INE0ATZ01017

KL Kronox Lab Sciences Ltd logo Broad data Nov 15, 2026

Kronox Lab Sciences Ltd

KRONOX · NSE

Expensive (fair value 25% below the price), but solid company and rising price: meets 2 of 3 rules.

Get notified free when this changes
Quality 70/100 
Rising price (uptrend) 
Healthy Growth (revenue 5y +10.1 %/yr in INR) 
Highly profitable · 26.6% net margin (TTM) 
Low debt 
Generates free cash flow 
0.3% dividend yield · Well covered
Broad data 
Mixed vs. peers (6/14) 
Wide moat 90/100 · thin data
Changed on Oct 20: ₹55.94 → ₹139.48 
Fair value ₹136.64 · Overvalued 
⟳ CyclicalQuality growth
Watch Kronox Lab Sciences Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹220.10 ₹96.74 Fair Value ₹136.64 Jun 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

29‑month range ₹96.74 – ₹220.10 · fair‑value band ₹90.48 – ₹200.80 · the ₹181.46 price screens above the ₹136.64 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.

Follow Kronox Lab Sciences in your weekly email

Every Wednesday you see whether Kronox Lab Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Kronox Lab Sciences Limited manufactures and sells fine chemicals, inorganic chemicals, phosphates, and metallic chemicals in India and internationally.

Show moreShow less

The company provides bulk reagents comprising ACS reagents, as well as LR, AR, and GR reagents; bulk ingredients that includes oral care, pharmacopoeia, food and nutraceutical, personal care and cosmetics, and veterinary pharma and animal health; and specialty chemicals, such as tartrates, citrates, hypophosphites, phosphates, hydroxides, EDTA and derivatives, ultra high purity chemicals, custom specification, and specialty anhydrous, as well as heat treatment, quenching, eutectic salt.

Kronox Lab Sciences Limited was incorporated in 2008 and is based in Vadodara, India.

Stock analysis

Kronox Lab Sciences Ltd (KRONOX) currently trades at ₹181.46, while our model-based Fair Value estimate is ₹136.64, 25% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of ₹109.27 per share, and 1 of the 26 models we run sit above the ₹181.46 price.

Bear case: the Asset-Based group reads lowest at ₹18.18, and 25 of the 26 models stay below the price. Data coverage for this calculation is high.

Scenario range: ₹90.48 (bear) to ₹200.80 (bull), the price of ₹181.46 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 70/100 (solid quality), in the Basic Materials sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Kronox Lab Sciences Ltd reported revenue of ₹1.0B in FY2026 versus ₹822M in FY2022, a compound +5.3%/yr. Reported net income was ₹277M in FY2026, compounding +19.4%/yr from FY2022.

Key figures

Market cap ₹6.7B (≈ $71.4M) Micro · P/E ratio 23.5 · P/S ratio 6.35 · EPS (TTM) ₹7.73 · Dividend yield 0.3% · Net margin 26.6% · Return on equity 24.7% · Return on assets (EBIT) 32.9% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 90 out of 100 (low confidence).

What moves the price

The share trades about 17% below its 52-week high and 88% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Basic Materials peers we cover trades at −43% fair-value upside, at −25%, KRONOX screens cheaper than that median.

Fair Value models

Bear ₹90.48 Fair Value ₹136.64 Bull ₹200.80
Price ₹181.46 · Downside -24.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 8 months old). Earnings retained since then (₹4.58 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF ₹40.60 ₹56.69 ₹76.62 81
Growth DCF ₹40.10 ₹54.25 ₹70.63 80
Owner Earnings ₹47.23 ₹65.98 ₹89.20 77
All 26 models by family
DCF Models
FCF DCF ₹40.60 ₹56.69 ₹76.62 81
Owner Earnings ₹47.23 ₹65.98 ₹89.20 77
5Y Revenue Exit ₹33.81 ₹50.01 ₹70.48 73
5Y EBITDA Exit ₹51.47 ₹84.56 ₹124.20 74
5Y P/E Exit ₹63.27 ₹107.63 ₹156.12 70
10Y Revenue Exit ₹35.99 ₹49.68 ₹68.01 67
10Y EBITDA Exit ₹45.24 ₹68.32 ₹100.40 68
10Y P/E Exit ₹51.06 ₹80.77 ₹119.65 63
Earnings-Based
Graham-Dodd ₹50.69 ₹195.78 ₹265.42 64
Lynch FV ₹51.45 ₹73.50 ₹95.56 61
PEG = 1.0 ₹51.45 ₹73.50 ₹95.56 57
EPV ₹36.80 ₹40.37 ₹43.17 74
Dividend Discount
Gordon GGM ₹2.93 ₹4.47 ₹5.44 69
DDM Multi-Stage ₹2.93 ₹4.43 ₹4.84 67
Multiples
P/E Multiple ₹95.05 ₹126.73 ₹158.41 63
P/S Multiple ₹30.69 ₹40.92 ₹51.15 58
P/B Multiple ₹70.41 ₹93.87 ₹117.34 55
EV/EBIT ₹91.49 ₹121.89 ₹152.29 66
EV/EBITDA ₹69.58 ₹92.67 ₹115.76 67
EV/Revenue ₹28.95 ₹41.23 ₹53.50 53
Asset-Based
NCAV (Graham) ₹12.00 ₹18.18 ₹22.72 54
Growth DCF
Growth DCF ₹40.10 ₹54.25 ₹70.63 80
Rev-Margin DCF ₹33.81 ₹50.39 ₹70.76 73
Economic Profit
Residual Income ₹32.35 ₹41.23 ₹59.24 75
ROIC Compounder ₹37.89 ₹43.79 ₹50.17 72
Growth Earnings
Growth-Adj P/E ₹76.49 ₹109.27 ₹142.05 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 70/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 83
How much profit the company makes from its sales and capital
Quality Growth 42
Are margins and returns getting better?
Cashflow 69
Do the profits arrive as real cash?
Financial strength 81
Debt, balance sheet and risk of trouble
Investment 31
Does it invest with discipline instead of growing at any price?
Low Volatility 40
How calm the share price moves, does not count
Price momentum 76
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 66
Distance to the 52-week high, does not count
New shares 84
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 91/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+1.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.1%
Start year 2021 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.2%
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+23.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+23.3%
Dividend (yield on the price)0.3%
Profit margin 2022 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.22% → 32%

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+30.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +25.4% a year for the price.

KRONOX screens overvalued: fair value 25% below the price. Compare with Linde plc →

Compare Kronox Lab Sciences Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 756 stocks

Beats the industry median on 6/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 70 · Top 25%
Fair Value upside −25.4% · Below median
Profitability
Return on equity (12 months) 24.7% · Top 25%
Return on assets 21.7% · Top 25%
Net margin (12 months) 26.6% · Top 25%
Operating margin (12 months) 31.3% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 5.1% · Below median
Dividend yield (12 months) 0.3% · Bottom 25%
Balance sheet
Debt / equity 0.01× · Lowest 25%

Valuation Multiplesvs Specialty Chemicals median · lower = cheaper

P/E (12 months) 23.5× · Pricier than median
P/B 5.83× · Priciest 25%
P/S (12 months) 6.35× · Priciest 25%
Price / free cash flow (fiscal year) 32.9× · Pricier than median
EV/EBITDA 19.1× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 6
FUTURE (revenue growth)26 · sector 68
PAST (return on equity)99 · sector 26
HEALTH (low debt)100 · sector 95
DIVIDEND (yield)5 · sector 31

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Wanhua Chemical Group 600309 ¥69.50 ¥68.03 −2% vs KRONOX
Linde plc LIN $523.46 $446.62 −15% vs KRONOX
PPG Industries, Inc PPG $121.97 $77.68 −36% vs KRONOX
DSM-Firmenich AG DSFIR CHF 96.60 CHF 58.32 −40% vs KRONOX
Asian Paints Limited ASIANPAINT ₹2,573 ₹1,479 −43% vs KRONOX
The Sherwin-Williams Company SHW $350.54 $152.59 −56% vs KRONOX
Givaudan SA GIVN CHF 4,091 CHF 1,618 −60% vs KRONOX
EMS-CHEMIE HOLDING AG EMSN CHF 839.00 CHF 284.63 −66% vs KRONOX
Ecolab Inc ECL $308.41 $97.18 −68% vs KRONOX
Air Products and Chemicals, Inc APD $313.90 $75.33 −76% vs KRONOX

Explore undervalued stocks

More undervalued Basic Materials stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Kronox Lab Sciences Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Kronox Lab Sciences Ltd Fair Value". https://www.fairvalue-calculator.com/stock/KRONOX

Frequently asked questions

Is Kronox Lab Sciences Ltd (KRONOX) overvalued or undervalued?
As of Nov 15, 2026, our model estimates a fair value of ₹136.64 versus a price of ₹181.46, about 25% lower (overvalued).
What is the fair value of KRONOX?
Our model-based fair value for Kronox Lab Sciences Ltd is ₹136.64 (as of Nov 15, 2026), built from audited fundamentals. The current price: ₹181.46.
What is the quality score of KRONOX?
Kronox Lab Sciences Ltd has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Kronox Lab Sciences Ltd (KRONOX)?
Our model-based price target is the fair value of ₹136.64 (as of Nov 15, 2026) from 26 valuation models. Cautious scenario ₹90.48, optimistic scenario ₹200.80. It is a calculation from audited fundamentals, not an analyst target.
What is the Kronox Lab Sciences Ltd stock forecast for 2026?
Our models put fair value at ₹136.64, about 25% lower versus a price of ₹181.46 (overvalued). Cautious scenario ₹90.48, optimistic scenario ₹200.80. The calculation is refreshed regularly with new filings.
What is the revenue of Kronox Lab Sciences Ltd (KRONOX)?
Kronox Lab Sciences Ltd reported trailing-twelve-month revenue of about ₹1.1B (latest available figure, as of Nov 15, 2026).
Does Kronox Lab Sciences Ltd pay a dividend?
Kronox Lab Sciences Ltd currently shows a dividend yield of 0.28% relative to its recent price (as of Nov 15, 2026).
How much is the dividend of Kronox Lab Sciences Ltd (KRONOX) and when is the ex-dividend date?
Kronox Lab Sciences Ltd pays a dividend of ₹0.5 per share a year, a dividend yield of 0.3%. The last ex-dividend date was Sep 9, 2026. The payout ratio is 6.5% of earnings. Free cash flow covers the dividend 11.10 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Kronox Lab Sciences Ltd (KRONOX)?
For today's price to be fair in a discounted-cash-flow model, Kronox Lab Sciences Ltd would have to grow free cash flow by 30.6 % per year for five years (discount rate 15.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 10.1 % per year. As of Nov 15, 2026.
What discount rate (WACC) does the fair value of KRONOX use?
Our models discount Kronox Lab Sciences Ltd at 15.3 %: a base by market capitalisation (micro), damped by beta 0.97, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Kronox Lab Sciences Ltd that is +30.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (15.3 %) and the same formula as our fair value.
How much growth has Kronox Lab Sciences Ltd (KRONOX) delivered so far?
Over the past 5 years revenue at Kronox Lab Sciences Ltd grew 10.1 % a year. The price currently implies free-cash-flow growth of +30.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Kronox Lab Sciences Ltd (KRONOX) growing?
The median revenue growth in the sector is +13.6 % a year. That is the yardstick for the growth priced into Kronox Lab Sciences Ltd (+30.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Kronox Lab Sciences Ltd (KRONOX)?
The free-cash-flow yield on the price is 3.07 %: that much free cash flow Kronox Lab Sciences Ltd produces per unit of market value. When it exceeds the discount rate of our models (15.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Kronox Lab Sciences Ltd (KRONOX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Kronox Lab Sciences Ltd it is ₹136.64 per share (as of Nov 15, 2026), against a price of ₹181.46. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Kronox Lab Sciences Ltd stock overvalued or undervalued in 2026?
As of Nov 15, 2026, KRONOX trades above its calculated fair value: price ₹181.46, fair value ₹136.64, a gap of about −25% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of KRONOX?
No. The price is what the market pays today (₹181.46); the fair value is what the company's own numbers justify (₹136.64). For Kronox Lab Sciences Ltd the two are ₹44.82 per share apart. That gap is exactly why we show both numbers side by side.
How much is Kronox Lab Sciences Ltd worth?
The market values Kronox Lab Sciences Ltd at about ₹6.7B (market capitalisation, as of Nov 15, 2026). Per share that is ₹181.46; our models calculate a fair value of ₹136.64 per share.
What do the bullish and bearish scenarios say about KRONOX?
Our models span a range for Kronox Lab Sciences Ltd: cautious scenario ₹90.48, base ₹136.64, optimistic ₹200.80 per share (as of Nov 15, 2026, price ₹181.46). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of KRONOX?
Kronox Lab Sciences Ltd trades at a price-to-earnings ratio of 23.5 (as of Nov 15, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹136.64 is built from several models across several years. Other multiples: P/B 5.8, P/S 6.4, EV/EBITDA 19.1.
How solid is the balance sheet of Kronox Lab Sciences Ltd (KRONOX)?
Balance-sheet figures for Kronox Lab Sciences Ltd (as of Nov 15, 2026): return on equity 24.7%, debt of 0.01 per unit of equity. They feed the Quality Score of 70/100, which measures business quality independently of the share price.
How far is KRONOX from its 52-week high?
Kronox Lab Sciences Ltd trades at ₹181.46, about 17% below its 52-week high of ₹218.79 and 88% above the low of ₹96.74 (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of ₹136.64 is for.
Which stocks are comparable to Kronox Lab Sciences Ltd?
From the same area (Basic Materials) we also value Linde plc, Ecolab Inc, The Sherwin-Williams Company, Air Products and Chemicals, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Kronox Lab Sciences Ltd stock attractive at the current price?
The data as of Nov 15, 2026: price ₹181.46, calculated fair value ₹136.64 (−25%), Quality Score 70/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of KRONOX calculated?
We run Kronox Lab Sciences Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹136.64 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Kronox Lab Sciences Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Kronox Lab Sciences Ltd (KRONOX)?
The closing price on Nov 17, 2026 was ₹181.46. Our model-based fair value is ₹136.64, about 25% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Kronox Lab Sciences Ltd right now?
Solid but not exceptional quality (70/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (₹90.48 to ₹200.80) leaves room in how you read the outcome.

Key figures of Kronox Lab Sciences Ltd

How large is the market capitalisation of Kronox Lab Sciences Ltd (KRONOX)?
The market capitalisation of Kronox Lab Sciences Ltd is ₹6.7B (≈ $71.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Kronox Lab Sciences Ltd (KRONOX)?
The price-to-sales ratio of Kronox Lab Sciences Ltd is 6.35 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Kronox Lab Sciences Ltd (KRONOX)?
Earnings per share at Kronox Lab Sciences Ltd are ₹7.73 (price ÷ EPS = P/E 23.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Kronox Lab Sciences Ltd (KRONOX)?
The dividend yield of Kronox Lab Sciences Ltd is 0.3% (payout 6.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Kronox Lab Sciences Ltd (KRONOX)?
The net margin of Kronox Lab Sciences Ltd is 26.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Kronox Lab Sciences Ltd (KRONOX)?
The return on equity (ROE) of Kronox Lab Sciences Ltd is 24.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Kronox Lab Sciences Ltd (KRONOX)?
On an EBIT basis the return on assets of Kronox Lab Sciences Ltd is 32.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Kronox Lab Sciences Ltd (KRONOX)?
The operating margin of Kronox Lab Sciences Ltd is 31.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Kronox Lab Sciences Ltd (KRONOX)?
Revenue at Kronox Lab Sciences Ltd is growing 5.1% versus a year earlier (3y avg +1.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Kronox Lab Sciences Ltd (KRONOX)?
Earnings per share at Kronox Lab Sciences Ltd are down 4.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Kronox Lab Sciences Ltd (KRONOX) hold?
Kronox Lab Sciences Ltd holds more cash than debt, ₹11.4M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Kronox Lab Sciences Ltd in the live analysis

One click puts Kronox Lab Sciences Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.